ZBIO
Income statement / Annual
Last year (2024), Zenas Biopharma Inc.'s total revenue was $5.00 M,
a decrease of 90.00% from the previous year.
In 2024, Zenas Biopharma Inc.'s net income was -$156.99 M.
See Zenas Biopharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$5.00 M |
$50.00 M |
$0.00 |
| Cost of Revenue |
$139.14 M
|
$0.00
|
$61.69 M
|
| Gross Profit |
-$134.14 M
|
$50.00 M
|
-$61.69 M
|
| Gross Profit Ratio |
-26.83
|
1
|
0
|
| Research and Development Expenses |
$139.14 M
|
$60.03 M
|
$62.69 M
|
| General & Administrative Expenses |
$28.85 M
|
$17.11 M
|
$12.81 M
|
| Selling & Marketing Expenses |
$900.00 K
|
$0.00
|
$700.00 K
|
| Selling, General & Administrative Expenses |
$29.75 M
|
$17.11 M
|
$13.51 M
|
| Other Expenses |
-$139.14 M
|
$10.00 M
|
-$61.69 M
|
| Operating Expenses |
$29.75 M
|
$87.15 M
|
$14.51 M
|
| Cost And Expenses |
$168.89 M
|
$87.15 M
|
$76.20 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$137.00 K
|
$113.00 K
|
$78.00 K
|
| EBITDA |
-$163.75 M |
-$27.03 M |
-$75.12 M |
| EBITDA Ratio |
-32.75
|
-0.54
|
0
|
| Operating Income Ratio |
-32.78
|
-0.74
|
0
|
| Total Other Income/Expenses Net |
$7.33 M
|
$324.00 K
|
-$43.08 M
|
| Income Before Tax |
-$156.56 M
|
-$36.82 M
|
-$119.28 M
|
| Income Before Tax Ratio |
-31.31
|
-0.74
|
0
|
| Income Tax Expense |
$429.00 K
|
$301.00 K
|
$0.00
|
| Net Income |
-$156.99 M
|
-$37.12 M
|
-$119.28 M
|
| Net Income Ratio |
-31.4
|
-0.74
|
0
|
| EPS |
-3.76 |
-0.97 |
-3.11 |
| EPS Diluted |
-3.76 |
-0.97 |
-3.11 |
| Weighted Average Shares Out |
$41.79 M
|
$38.32 M
|
$38.32 M
|
| Weighted Average Shares Out Diluted |
$41.79 M
|
$38.32 M
|
$38.32 M
|
| Link |
|
|
|
